Interleukin-12 (IL-12) plays a key role in promoting T helper 1 (Th1) responses and subsequent cell-mediated immunity. Given the role of cytokines in the pathogenesis of psychiatric disorders, the dysregulation of IL-12 in these illnesses would be expected. We measured the plasma levels of IL-12 in 102 psychiatric patients (43 schizophrenia, 34 major depression and 25 bipolar disorder) and 85 normal controls. In addition, IL-12 levels of the patients were measured after an 8-week treatment to assess whether the levels were affected by medication. The IL-12 levels of the patient group with major depression were significantly higher than that of the control group, whereas no differences were found among the other groups. IL-12 values of the three patient groups decreased significantly after 8 weeks of treatment. These findings support the hypothesis that activation of the inflammatory response system and in particular of Th-1-like cells, is involved in the pathophysiology of major depression and that repeated administration of antidepressive and antipsychotic drugs may suppress IL-12 plasma concentrations in psychiatric patients.
Introduction
Over the past 10 years, it has been hypothesized that schizophrenia and major depression may be accompanied by an activation of inflammatory response system, which could be related to the pathophysiology or etiology of those illnesses. The macrophage-T lymphocyte theory of schizophrenia 1, 2 has proposed that chronically activated macrophages and T lymphocytes, along with excessive interleukin-2 and other cytokine secretions are a cause of some cases of schizophrenia. Similarly, the monocyte-T-lymphocyte hypothesis of major depression 3 also suggested that activation of peripheral blood monocytes and T lymphocytes play a role in the pathophysiology or pathogenesis of that illness. 4, 5 Schizophrenia is characterized by increased nonspecific innate immunity, decreased type 1 T helper cell (Th1)-specific cellular immunity, and a Th1-Th2 imbalance with a shift to the Th2 system. 6 The innate immune activation in schizophrenia has been based on the findings of increased monocyte numbers, increased activity of macrophage, increased proinflammatory cytokine levels such as IL-1, IL-6, IL-18 and tumor necrosis factor(TNF)-␣. [7] [8] [9] [10] [11] Schizophrenia is also characterized by a decrease in IL-2 production [12] [13] [14] and interferon(IFN)-␥, 7, 15 traditionally classified as Th1 cytokines, and an increase in IL-4 16 and IL-10, 17, 18 traditionally classified as Th2 cytokines. On the other hand, there have been reports of an increased Th1 system in schizophrenia, specifically an increased IL-2 level in plasma 19 and in cerebrospinal fluid 20, 21 and increased production of IL-2 and IFN-␥. 22 Interestingly, in our previous study, 13 we found that decreased IL-2 production may be associated with an increased IL-2 serum level in schizophrenic patients, supporting the T cell exhaustion theory that lower IL-2 production may be induced by a consequence of overproduction of in vivo IL-2.
It has been postulated that major depression may be accompanied by significant changes in cell-mediated and humoral immunity, and these changes may be related to the pathophysiology or pathogenesis of that illness. [23] [24] [25] [26] Pro-inflammatory cytokines including IL-1␤, 4 IL-6, 9 and TNF-␣ 27 in blood are increased in major depression. These findings suggest that innate immunity is activated by secretion from monocytes and Molecular Psychiatry macrophages during major depression. Moreover, Licinio and Wong 25 suggested that brain cytokines, principally IL-1␤ and IL-1 receptor antagonist, may have a role in the biology of major depression, and that central and peripheral cytokine compartments are integrated but differentially regulated.
Reports on the assessment of the inflammatory response system in bipolar mania are limited and remain controversial, but cell-mediated immunity activation in bipolar mania has been suggested. There have been some reports that bipolar mania is related to the activation of the inflammatory response system, characterized by increased plasma concentrations of soluble interleukin-2 receptor (sIL-2R) and sIL-6R, [28] [29] [30] and increased acute phase proteins. 31 If the cytokine abnormalities play a causative role in the pathophysiology of psychiatric disorders, it is not unreasonable to hypothesize that psychotropic drugs may be able to suppress the release of cytokines. Actually, typical antipsychotic drugs (eg haloperidol) seem to have negative immunoregulatory effects 19, 28, 32 and atypical neuroleptics (eg clozapine and risperidone) appear to have complex in vivo immunomodulatory effects. 33, 34 On the one hand, antidepressants impair the release of proinflammatory cytokines from activated monocytes and macrophages and enhance the expression of anti-inflammatory cytokines. For example, clomipramine, sertraline, and trazodone inhibit the stimulated production of IFN-␥, whereas clomipramine and sertraline increased the production of IL-10 in an in vitro study. 35 Interleukin-12 (IL-12) is a heterodimeric cytokine that is produced primarily by monocytes and macrophages. 36 IL-12 plays a central role in promoting Th1 responses and, hence, cell-mediated immunity. 37 This function is promoted by the IL-12-induced production of IFN-␥ from both resting and activated natural killer (NK) cells and T cells, by enhancing the cytotoxic activity of NK cells, and by cytotoxic T lymphocyte generation. Thus, IL-12 is a proinflammatory cytokine with immunoregulatory functions that bridge innate resistance and antigen-specific adaptive immunity. 38 IL-12 produced during early phases of infection and inflammation sets the stage for the ensuing antigen-specific immune response, favoring differentiation and function of Th1 T cells while inhibiting the differentiation of Th2 T cells. 39 Thus, given the role of IL-12 in the cascade of cytokine regulation, we hypothesized that another pro-inflammatory cytokine, IL-12 could be dysregulated in some psychiatric disorders. To our knowledge, studies of IL-12 have not been undertaken in the field of psychiatry. Hence, we measured the plasma levels of IL-12 in a large cohort of 102 psychiatric patients (43 schizophrenia, 34 major depression and 25 bipolar disorder) and 85 normal controls. In addition, IL-12 levels of the patients were measured after an 8-week treatment to assess whether the levels were affected by medication. It was hypothesized that if the monocyte-T lymphocyte hypothesis of schizophrenia or major depression is correct, increased plasma levels of IL-12 should be found in schizophrenia and major depression, and that upon treatment these increased levels may return to baseline.
Subjects and methods

Subjects
Among psychiatric patients newly admitted in closed wards of the Department of Psychiatry, Korea University Medical Center, during August 1999 to June 2001, we recruited 102 psychiatric patients (43 schizophrenia, 34 major depression, and 25 bipolar mania) who met the Diagnostic and Statistical Manual (DSM-IV) criteria. 40 Each patient was given a diagnostic assessment based on clinical interviews using a Structured Clinical Interview for DSM-IV. 41 All patients had psychotic or active symptoms at the time of study enrollment. All patients were either medication-naive (first-onset) or medication-free for at least 4 months. The patients gave informed consent after the procedure had been fully explained.
The psychopathological status of the patients was assessed by a trained physician (Y-K Kim) using the Brief Psychiatric Rating Scale 42 for patients with schizophrenia, the Hamilton Rating Scale 43 for Depression for patients with major depression, and the Rating Scale 44 for Mania for bipolar mania. Each patient's symptoms were assessed on admission and 8 weeks later by the same physician.
Twenty-nine of 43 schizophrenic patients, 17 of 34 major depressive disorder patients, and 17 of 25 bipolar manic disorder patients completed the 8-week study. The high rate of drop-outs in our study was caused by the study protocol to include patients only in hospitalization for the 8 weeks of study. The reasons for the failure of follow-up included the change to outpatient department treatment before the termination of the study (91.4%) and the switch to other drugs due to adverse effect or unresponsiveness (9.6%). Among the schizophrenia patients, 17 patients were medicated with risperidone (mean 7.5 mg; range 6-14 mg), five patients with olanzapine (mean 16 mg; range 10-20 mg), four patients with nemonapride (mean 13.2 mg; range 8-18 mg), two patients with clozapine (270 mg and 300 mg), and one patient with haloperidol (21 mg). Among the major depression patients, seven patients were medicated with nefazodone (mean 318 mg; range 100-450 mg), six patients with paroxetine (mean 36.6 mg; range 20-40 mg), three patients with fluoxetine (mean 46.6 mg; range 40-60 mg), and one patient with venlafaxine (300 mg). Among these major depressive disorder patients, five patients were also given an antipsychotic medication (haloperidol or risperidone) for controlling psychotic symptoms. Among the patients with bipolar disorder, nine patients were medicated with lithium (mean 1050 mg day −1 ; range 900-1500 mg day −1 ), six patients with valproate sodium (mean 1037.5 mg day −1 ; range 900-1200 mg day −1 ), and two patients with both lithium and valproate sodium. Three of the 17 bipolar disorder patients also took an antipsychotic medication (risperidone or olanzapine) for controlling psychotic symptoms.
Patients with a history of any concomitant psychiatric illness, such as substance or alcohol abuse, a history of infection, or a known autoimmune disease were excluded. Patients were found to have a normal physical state as seen from normal values of blood and urine tests, such as SGOT, SGPT, hemoglobin, hematocrit, serum electrolytes, blood urea, and creatine. Patients were given a standard set of tests by the Venereal Disease Research Laboratory (VDRL) and had normal electrocardiograms (EKG) and electroencephalograms (EEG). The laboratory tests were rechecked after 8 weeks and were not significantly different compared with the admission.
Eighty-five healthy controls were recruited among healthy individuals who visited the same hospital for regular health screening during the same time period as the patients. Each patient was given a non-structured clinical interview. Patients with any personal or familial history of psychiatric illness, diagnosed autoimmune disease, or substance or alcohol abuse were excluded. All subjects were free of chronic and acute physical illness (such as infectious or allergic diseases) associated with abnormal cell-mediated immunity within the 2 weeks before the study. They showed normal laboratory findings in blood chemistry, renal function, thyroid function, liver function, VDRL tests, chest X-ray of the lungs and heart, EKG, and EEG.
Methods
Ten ml of fasting blood were withdrawn with a lithium heparin vacuum tube between 8.00 am and 9.00 am and immediately centrifuged at 3800 rpm for 10 min. Plasma was stored at −70°C until thawed for assay. For the three patient groups, blood was sampled both on admission and 8 weeks later.
The plasma concentrations of IL-12 were measured by an enzyme-linked immunosorbent assay (ELISA) technique using a commercially available kit (Quantikine; R&D Systems, USA) according to the manufacturer's instructions. In brief, these assays are performed in a microplate using the quantitative sandwich enzyme immunoassay technique with a monoclonal antibody specific for IL-12. Ninety-six-well polystyrene microtiter plates were pre-coated with a murine monoclonal antibody specific for IL-12. Standards and samples were pipetted into the wells, incubated 2 h at room temperature, washed each well with wash buffer twice, added 200 l of IL-12 conjugate to each well, incubated 1.5 h at room temperature, washed twice, added 200 l of substrate solution, incubated for 20 min at room temperature, added 50 l of stop solution. The optical density of each well was measured using a microplate reader (Coda automatic EIA analyzer; Bio-Rad, USA) set to 450 nm and corrected wavelength set to 540 nm. Duplicate readings were averaged for each standard, control, and sample, subtracting the average zero standard optical density. For the standard curve, the data points were linearized by plotting the log of the IL-12 concentration vs the log Molecular Psychiatry of the optical density, and the best fit line was determined by regression analysis. The IL-12 level of each sample was determined by the concentration read from the standard curve. The intra-and inter-assay coefficients of variance were less than 5%. All assays for both patients and controls were carried out in the same run in duplicate by the same operator (I-B Suh). Table 1 lists the demographic data of the 187 study subjects. There were no significant differences in the male:female ratio between the four study groups ( 2 = 6.55; df = 3; P = 0.09), and there were no significant differences in body mass index (BMI) between the three diagnostic groups (F = 0.53; df = 3; P = 0.66). However, the control and bipolar mania patient groups were significantly younger than the depression patient group (F = 6.23; df = 3; P = 0.0005), and in each group male patients were significantly younger than female patients (F = 8.02; df = 1; P = 0.005).
Statistical analysis
Study groups were compared for continuous covariates by a two-tailed t-test or an analysis of variance with the Dunnett or Scheffe test. A multiple comparison method of the Dunnett test was used when three disease groups were compared to the control group, and the Scheffe test was used for all pairwise comparisons. For discrete covariates, study groups were compared by a chi-square test. The pre-and post-treatment IL-12 values of patient groups were compared by repeated measures analysis of variance. Pearson's product moment correlation coefficients were calculated to examine the relationships between IL-12 level and clinical variables. The null hypothesis was rejected at P Ͻ 0.05.
Results
Demographic data
Plasma IL-12 levels
After adjusting for age differences (F = 0.29; P = 0.59), there were highly significant differences among the IL-12 values among the four study groups (F = 3.49; df = 3; P = 0.017). The IL-12 values of the depression group were significantly higher than those of the control group (Scheffe test, P Ͻ 0.05), whereas no differences were found between other groups (Figure 1 ). Within each diagnostic group, there were no significant differences of IL-12 levels among subgroups of patients with different disease subtypes or taking different medications (data not shown). Concerning the effect of smoking, IL-12 level did not differ between smokers and non-smokers among the 102 patients (smokers, n = 35, 12.6 ± 11.7 pg ml ; non-smokers, n = 67, 11.6 ± 9.7 pg ml −1 , t = 0.43, df = 100, P = 0.6), nor among the 85 controls (smokers, n = 22, 9.7 ± 4.3 pg ml −1 ; nonsmokers, n = 63, 9.2 ± 3.3 pg ml −1 , t = 0.47, df = 83, P = 0.6). In the 102 patients, no significant correlations were found between IL-12 levels and any clinical variable including age, duration of illness, age of onset, 26.5 ± 9.6 (n = 43) 25.4 ± 6.8 (n = 34) 32.6 ± 6.9 (n = 25) At 8 weeks 11.3 ± 9.6 (n = 29) 5.2 ± 4.1 (n = 17) 1.8 ± 2.6 (n = 17) a The psychopathological scores were based on the Brief Psychiatric Rating Scale for patients with schizophrenia, the Hamilton Rating Scale for Depression for patients with major depression, and the Rating Scale for Mania for patients with bipolar mania. BMI, number of admissions, number of episodes, and psychopathology scores (data not shown).
Changes in IL-12 levels before and after 8 weeks of treatment
Sixty-three patients (29 schizophrenia, 17 major depression, and 17 bipolar mania) completed the 8-week trial and were included in a second analysis. Within each diagnostic group, there were no significant differences of IL-12 levels between the drop-outs and the patients who complete the 8 week trial (data not shown).
The changes in IL-12 levels between before and after treatment were analyzed by repeated measures analysis of variance. Body weight was used as a covariate, since there were significant differences in weight gains among the three patients groups, with more weight gains for bipolar mania patients compared to schizophrenia patients (F = 3.63; df = 2; P = 0.03). IL-12 values of the three patient groups were significantly lower after 8 weeks of treatment (F = 4.40; df = 1; P = 0.04) (Figure 2) . The IL-12 values of the three groups were significantly different (F = 7.36; df = 2; P = 0.0015). The IL-12 values between male and female patients were significantly different (F = 9.90; df = 1; P = 0.0026). The interaction effect of three patients groups and sex was significant (F = 7.06; df = 2; P = 0.0018). Since the interaction of three groups and sex was significant, we made a separate analysis for each sex; among male patients, the IL-12 values of the depression group were the highest of all patient groups (F = 5.83; df = 2; P = 0.0134), but among female patients no significant differences in IL-12 values between the three patient groups were found (F = 0.46; df = 2; P = 0.6329). There were no significant correlations between the changes of IL-12 and the changes of the psychopathology scores (data not shown).
Discussion
The first major finding of this study is that major depressive disorder patients had significantly higher plasma levels of IL-12 than normal controls. Moreover, this result remained significant, even after adjusting for age. The finding of increased IL-12 levels in major depression may contribute to the activation of immune response in that illness. Indeed, there is now strong evidence that major depression may be accompanied by significant changes in cell-mediated and humoral immunity. There is some evidence for increased production of pro-inflammatory cytokines such as IL-1␤, IL-6, TNF-␣, and IFN-␥ in culture supernatant of mitogen-stimulated peripheral blood mononuclear cells (PBMC), increased serum concentrations of IL-6 and IL-2, and changes in the concentrations of some of the respective receptors, such as the IL-2 and the IL-6 receptor in major depression. 5, 24, 45 Moreover, increased neutrophil and monocyte phagocytosis has been Molecular Psychiatry observed in depressed patients. 46 IL-12 is produced primarily by the antigen-presenting cells and exerts immunoregulatory effects on T and NK cells, and regulates the balance between type I (producing IL-2 and IFN-␥) and type 2 helper T cells (producing IL-4 and IL-10). 36, 37 Thus, the finding of increased IL-12 in our major depressed patients may be considered as additional evidence for an inflammatory response system during major depression.
For schizophrenia and bipolar mania, we did not find significant differences in IL-12 levels between these two diagnostic groups and controls. These findings were contrary to our expectation that IL-12 would be higher in schizophrenia, since the signs of an inflammatory disease process have been documented in schizophrenia. 6, 47 However, it is worthy of note that though the means of IL-12 levels of two diagnostic groups were not different from those of normal controls, the standard deviation between schizophrenia and normal controls was quite large (10.3 vs 2.5, respectively). This finding suggests a considerable heterogeneity in the levels of IL-12 among individual schizophrenic patients. Therefore, it is possible that there is, in fact, a subgroup of schizophrenic patients who have markedly elevated IL-12 during episodes, while others have normal levels even during episodes. This result could further suggest that the immune abnormalities may occur only in a subgroup of patients with schizophrenia. This concept is supported by a previous study 48 that treatment-resistant schizophrenia (TRS) had significantly higher serum IL-6 levels than healthy volunteers, whereas patients with non-TRS did not differ in serum IL-6 levels from controls. In contrast, bipolar mania patients did not differ much from normal controls regarding the standard deviation (3.5 vs 2.5, respectively). Although there have been some recent studies [29] [30] [31] showing an inflammatory response system in bipolar mania, our findings did not support the hypothesis of immune abnormalities in IL-12 in that illness.
The second major finding of this study is that the 8 weeks of treatment with psychotropic drugs resulted in significant decreases of IL-12 levels. Moreover, these findings were not affected by the weight changes in these patients. At the present time, we cannot clearly explain the mechanism of decreased IL-12 levels by the various drugs. However, considering the effects of psychotropic drugs on cytokines, it is possible that the immunosuppressive effects, mediated by decreased monocyte/macrophage functions, may be responsible for the reduced IL-12 levels and subsequent Th1-Th2 imbalance. As for antidepressants, it is reported that increased monocyte phagocytosis in depressed patients was reversed upon successful antidepressant treatments. 46 Also, levels of pro-inflammatory cytokines, such as IL-1␤ and IL-6, which are released mainly from monocytes and macrophages, returned to control levels over a 6-week period upon successful antidepressant treatment in major depression patients. 49, 50 Alternatively, in an in vitro study, 35 antidepressants inhibited the stimulated production of IFN-␥, while increasing the production of IL-10, an anti-inflammatory cytokine, in whole blood of healthy volunteers. Moreover, a variety of antidepressants including imipramine, venlafaxine, and fluoxetine are recently reported to have a common negative immunoregulatory effect by suppressing the IFN-␥:IL-10 ratio. 51 It has been reported that typical and atypical antipsychotic drugs can modulate the production of cytokines or cytokine receptors. Typical antipsychotic drugs such as haloperidol are known to have immunosuppressive activities through stimulation of the production of the IL-1 receptor antagonist and suppression of the production of inflammatory cytokines, such as IL-2, IL-6, and IFN-␥. 19, 32, 33, 52 Atypical antipsychotics such as risperidone and clozapine also appear to have anti-inflammatory activities, 32,52,53 although short-term treatment induces the production of pro-inflammatory cytokines such as IL-6, IFN-␥ and TNF-␣, but the effect disappears upon prolonged treatment. 31, 54, 55 In addition, the proportion of mononuclear phagocytes and macrophages in the CSF of schizophrenic patients was significantly higher before treatment, and returned to normal during treatment with conventional neuroleptic medication. 56 The effects of mood stabilizers such as lithium or valproate sodium on immune function are not clear, but some studies have suggested that lithium may have profound immunomodulatory effects in humans. Effective lithium treatment diminished the plasma concentration of acute phase proteins, a marker for the activation of the inflammatory response system. 31, 57 Lithium also reduced the soluble IL-6 receptors and the soluble IL-2 receptors to a normal level in symptomatic rapid cycling bipolar patients with a mild inflammatory response system. 29 Recently, it was found that lithium caused an increase in IL-4 and IL-10, classified as Th-2 cytokines, and a decrease in IL-2 and IFN-␥, classified as Th1 cytokines. 58 Taken together, it is speculated that psychotropic drugs are related to their negative immunoregulatory effects, and in this context, IL-12 levels would be decreased via the reduced monocyte/macrophage activity caused by the psychotropic drugs.
Whether IL-12 in our major depression patients plays a causative role in the pathophysiology of that illness is uncertain. Even if IL-12 levels in our depressed patients decreased significantly over the 8-week hospitalization period, during the same time as a decrease in HAM-D scores was apparent, we did not find a significant correlation between the changes of IL-12 and those of HAM-D scores. Therefore, further investigations regarding the temporal relationship between IL-12 and mood changes are needed to clarify its clinical significance.
Some potential limitations of the present study should be noted. First, because the plasma samples of our patients had different storage times (from 1 month to about 2 years), it is possible that this might have affected the results. However, in our patients, the storage time was not correlated with IL-12 concentrations (data not shown). Furthermore, a recent study 53 reported that the storage time within 3 years after the blood was collected did not affect the inflammatory response system. Second, our patients were prescribed a variety of psychotropic drugs. Though our result suggests that IL-12 had inhibiting effects independent of the class of psychotropic drugs, the immune system is composed of complex regulatory mechanisms. Due to the variable medication and the small groups of patients using similar drugs in this study, a further replication study that examines the effects of each psychotropic drug on IL-12 in the larger members of patients will be warranted. Third, it has been suggested that numerous confounding factors such as age, BMI, gender, smoking habits, ongoing or recent infectious diseases, or prior medication may affect the plasma levels of cytokines. 59 Coagulation can activate monocytes during blood sampling. 60 Thawing also increases IL-6 levels, and the type of tubes can affect cytokine measurements. 61 Hence, these factors deserve particular attention.
